Thyroid hormone and heart failure: From myocardial protection to systemic regulation

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 10, 2014, Pages 1227-1236

  Sabatino, Laura ^a   Iervasi, Giorgio ^a   Pingitore, Alessandro ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Heart failure; Hypothyroidism; Integrin; Low T3 syndrome; Thyroid hormone; Thyroid hormone receptors

Indexed keywords

LIOTHYRONINE; THYROID HORMONE; THYROID HORMONE RECEPTOR; VITRONECTIN RECEPTOR; THYROTROPIN;

CELL DIFFERENTIATION; CELL PROTECTION; CELL REGENERATION; COMORBIDITY; DISEASE ASSOCIATION; GENE CONTROL; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HORMONE ACTION; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE SYNDROME; NONHUMAN; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC DISEASE; ANIMAL; DISEASE COURSE; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS;

ANIMALS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; MYOCARDIUM; PROGNOSIS; THYROID HORMONES; THYROTROPIN;

EID: 84907433155     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.957674     Document Type: Review

References (75)

1. Bergh JJ, Lin HY, Lansing L, et al. Integrin aVb3 contains a cell surface receptor site or thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005;146:2864-71
2. Davis PJ, Davis FB, Cody V. Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab 2005;16:429-35
3. Moeller LC, Cao X, Dumitrescu AM, et al. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nucl Recept Signal 2006;4:e020
4. Pantos C, Mourouzis I. The emerging role of TRa1 in cardiac repair: potential therapeutic implications. Oxid Med Cell Longev 2014;2014:481482
5. Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008;29:211-18
6. Pantos C, Xinaris C, Mourouzis I, et al. Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling? Mol Cell Biochem 2007;297:65-72
7. Pantos C, Mourouzis I, Cokkinos DV. Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling. Vascul Pharmacol 2010;52:157-65
8. Kinugawa K, Yonekura K, Ribeiro RC, et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 2001;89:591-8
9. Kinugawa K, Jeong MY, Bristow MR, et al. Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol 2005;19:1618-28
10. Pantos C, Mourouzis I, Galanopoulos G, et al. Thyroid hormone receptor 1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res 2008;59:253-69
11. van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316:575-9
12. Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009;119:2772-86
13. Diniz GP, Takano AP, Barreto-Chaves ML. MiRNA-208a and miRNA-208b are triggered in thyroid hormone-induced cardiac hypertrophy-role of type 1 Angiotensin II receptor (AT1R) on miRNA-208a/a-MHC modulation. Mol Cell Endocrinol 2013;374:117-24
14. Mourouzis I, Forini F, Pantos C, Iervasi G. Thyroid hormone and cardiac disease: from basic concepts to clinical application. J Thyroid Res 2011;2011:958626
15. Kenessey A, Ojamaa K. Ligand-mediated decrease of thyroid hormone receptor-alpha1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability. Am J Physiol Heart Circ Physiol 2005;288:H813-21
16. Pantos C, Xinaris C, Mourouzis I. Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"? J Physiol Pharmacol 2008;59:253-69
17. Kenessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 2006; 281(30):20666-72
18. Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006;103:14104-9
19. Cao X, Kambe F, Moeller LC, et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 2005;19:102-12
20. McMullen JR, Shioi T, Huang WY, et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 2004;279:4782-93
21. Okumura H, Nagaya N, Itoh T, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/ Akt-dependent pathway. Circulation 2004;109:242-8
22. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010;31:139-70
23. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000;275:21785-8
24. Mousa SA, Bergh JJ, Dier E, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008;11:183-90
25. Baig MK, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216-30
26. Gerdes AM. Cardiac myocyte remodeling in hypertrophy and progression to failure. J Card Fail 2002;8:S264-8
27. Gerdes AM, Pingitore A. Assessment of cardiomyocyte size. In: Ardehali H, Bolli R, Losordo DW, editors. Manual of research techniques in cardiovascular medicine. 1st edition. John Wiley & Sons; NJ, USA: 2014:378-385
28. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990;68:1071-4
29. Lionetti V, Matteucci M, Ribezzo M, et al. Regional mapping of myocardial hibernation phenotype in idiopathic end-stage dilated cardiomyopathy. J Cell Mol Med 2014;18:396-414
30. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41
31. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988;242:941-4
32. Nakano M, Knowlton AA, Yokoyama T, et al. Tumor necrosis factor-alpha-induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am J Physiol 1996;270:H1231-9
33. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9
34. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev 2008;13:387-92
35. Newhouse A, Jiang W. Heart failure and depression. Heart Fail Clin 2014;10: 295-304
36. Gastelurrutia P, Lupón J, Altimir S, et al. Int J Cardiol Fragility is a key determinant of survival in heart failure patients. Int J Cardiol 2014. [Epub ahead of print]
37. Triposkiadis FK, Skoularigis J. Prevalence and importance of comorbidities in patients with heart failure. Curr Heart Fail Rep 2012;9:354-62
38. Lee CS, Chien CV, Bidwell JT, et al. Comorbidity profiles and inpatient outcomes during hospitalization for heart failure: an analysis of the U.S. Nationwide inpatient sample. BMC Cardiovasc Disord 2014;14:73
39. Pingitore A, Iervasi G. Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure. Recent Pat Cardiovasc Drug Discov 2008;3:19-27
40. Chuang CP, Jong YS, Wu CY, et al. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am J Cardiol 2014;113:845-50
41. Silva-Tinoco R, Castillo-Martínez L, Orea-Tejeda A, et al. Developing thyroid disorders is associated with poor prognosis factors in patient with stable chronic heart failure. Int J Cardiol 2011;147:e24-5
42. Passino C, Pingitore A, Landi P, et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J Card Fail 2009;15:35-40
43. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012;97:852-61
44. Iacoviello M, Guida P, Guastamacchia E, et al. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des 2008;14: 2686-92
45. Chen S, Shauer A, Zwas DR, et al. The effect of thyroid function on clinical outcome in patients with heart failure. Eur J Heart Fail 2014;16:217-26
46. Mitchell JE, Hellkamp AS, Mark DB, et al. Thyroid function in heart failure and impact on mortality. JACC Heart Fail 2013;1:48-55
47. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012;126:1040-9
48. Perez AC, Jhund PS, Stott DJ, et al. Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). JACC Heart Fail 2014;2:35-40
49. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010;304:1365-74
50. Chen S, Shauer A, Zwas DR, et al. The effect of thyroid function on clinical outcome in patients with heart failure. Eur J Heart Fail 2014;16:217-26
51. Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med 1995;333: 1562-3
52. Merla R, Martinez JD, Martinez MA, et al. Hypothyroidism and renal function in patients with systolic heart failure. Tex Heart Inst J 2010;37:66-9
53. McAlister FA, Ezekowitz J, Tarantini L, et al. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012;5:309-14
54. Drechsler C, Schneider A, Gutjahr-Lengsfeld L, et al. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients. Am J Kidney Dis 2014;63:988-96
55. Shin DH, Lee MJ, Lee HS, et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013;23:654-61
56. Meuwese CL, Dekkers OM, Stenvinkel P, et al. Nonthyroidal illness and the cardiorenal syndrome. Nat Rev Nephrol 2013;9:599-609
57. Palma CC, Pavesi M, Nogueira VG, et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetol Metab Syndr 2013;5:58-62
58. El-Eshmawy MM, Abd El-Hafez HA, El Shabrawy WO, et al. Subclinical hypothyroidism is independently associated with microalbuminuria in a cohort of prediabetic Egyptian adults. Diabetes Metab J 2013;37:450-7
59. Christy AL, Manjrekar P, Babu RP, et al. Elevation of HbA1C in Non-diabetic Hypothyroid Individuals: is Anaemia the Connecting Link?-A Preliminary Study. J Clin Diagn Res 2013;7:2442-4
60. Dayan CM, Panicker V. Hypothyroidism and Depression. Eur Thyroid J 2013;2: 168-79
61. Premachandra BN, Kabir MA, Williams IK. Low T3 syndrome in psychiatric depression. J Endocrinol Invest 2006;29:568-72
62. Bunevicius R, Lasas L, Kazanavicius G, et al. Pituitary responses to thyrotropin releasing hormone stimulation in depressed women with thyroid gland disorders. Psychoneuroendocrinology 1996;21:631-9
63. Bunevicius R, Varoneckas G, Prange AJ Jr, et al. Depression and thyroid axis function in coronary artery disease: impact of cardiac impairment and gender. Clin Cardiol 2006;29:170-4
64. Iervasi G, Sabatino L, Nicolini G. Low triiodothyronine syndrome as a powerful predictor of death in heart failure. In: Iervasi G, Pingitore A, editors. Thyroid and heart failure. Springer-Verlag; Italia: 2009: 179-190
65. Lubrano V, Pingitore A, Carpi A, et al. Relationship between triiodothyronine and proinflammatory cytokines in chronic heart failure. Biomed Pharmacother 2010;64:165-9
66. Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008;93:1351-8
67. Moruzzi P, Doria E, Agostoni PG, et al. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 1994;73:374-8
68. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 1996;101: 461-7
69. Hamilton MA, Stevenson LW, Fonarow GC, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998;81:443-7
70. Malik FS, Mehra MR, Uber PA, et al. Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. J Card Fail 1999;5:31-7
71. Iervasi G, Emdin M, Colzani RMP, et al. Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome. In: Kimchi A, editor. Second International Congress on Heart Disease-new trends in research, diagnosis and treatment. Medimond Medical Publications; Englewood, NJ, USA: 2001. p. 549-53
72. Goldman S, McCarren M, Morkin E, et al. DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 2009;119:3093-100
73. Curotto Grasiosi J, Peresotti B, Machado RA, et al. Improvement in functional capacity after levothyroxine treatment in patients with chronic heart failure and sublinical hypothyroidism. Endocrinol Nutr 2013;60:427-32
74. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18
75. Pingitore A, Iervasi G, Gerdes MA. Letter by Pingitore et al regarding article "DITPA (3-5-diidrothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study". Circulation 2010;121:e240